Regeneron Reports Fourth Quarter and Full Year 2019 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Regeneron (REGN) Tops Q4 EPS by 58c
February 6, 2020 6:32 AM ESTRegeneron (NASDAQ: REGN) reported Q4 EPS of $7.50, $0.58 better than the analyst estimate of $6.92. Revenue for the quarter came in at $2.17 billion versus the consensus estimate of $2.11 billion.
The Company and Sanofi announced intent to restructure antibody collaboration for Kevzara and Praluent2020... More
